Caspase 9 (CASP9) Human shRNA Plasmid Kit (Locus ID 842)

CAT#: TR305634

CASP9 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided

Specifications

Product Data

• Locus ID: 842
• Synonyms: APAF-3; APAF3; ICE-LAP6; MCH6; PPP1R56
• Vector: pRS
• E. coli Selection: Ampicillin
• Mammalian Cell Selection: Puromycin
• Format: Retroviral plasmids
• Kit Components: CASP9 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 842). 5µg purified plasmid DNA per construct
  29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
• RefSeq: NM_001229, NM_001278054, NM_032996, NR_102732, NR_102733, NM_001229.1, NM_001229.2, NM_001229.3, NM_001229.4, NM_032996.1, NM_032996.2, NM_032996.3, NM_001278054.1, BC006463, BC006463.1, BC002452, NM_001229.5
• UniProt ID: P55211
• Summary: This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein can undergo autoproteolytic processing and activation by the apoptosome, a protein complex of cytochrome c and the apoptotic peptidase activating factor 1; this step is thought to be one of the earliest in the caspase activation cascade. This protein is thought to play a central role in apoptosis and to be a tumor suppressor. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).